Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 822,968 |
|
|||||
| News | - | ||||||
| Day High | 45.84 | Low High |
|||||
| Day Low | 44.00 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Merus NV | MRUS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.11 | 0.24% | 45.04 | 17:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 44.66 | 44.00 | 45.84 | 45.04 | 44.93 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 8,983 | 822,968 | $ 45.23 | $ 37,226,919 | - | 18.21 - 52.035 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:56:59 | 10 | $ 45.99 | USD |
Merus NV Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 57.88M | - | 43.95M | -154.94M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Merus NV News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRUS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 40.56 | 45.84 | 39.27 | 42.44 | 947,106 | 4.48 | 11.05% |
| 1 Month | 45.45 | 46.56 | 39.27 | 42.72 | 593,911 | -0.41 | -0.90% |
| 3 Months | 35.83 | 52.035 | 35.06 | 44.38 | 616,367 | 9.21 | 25.70% |
| 6 Months | 20.30 | 52.035 | 19.805 | 36.89 | 522,832 | 24.74 | 121.87% |
| 1 Year | 20.20 | 52.035 | 18.21 | 31.41 | 423,693 | 24.84 | 122.97% |
| 3 Years | 23.61 | 52.035 | 12.03 | 26.03 | 350,744 | 21.43 | 90.77% |
| 5 Years | 16.35 | 52.035 | 10.18 | 24.62 | 249,426 | 28.69 | 175.47% |
Merus NV Description
| Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others. |
